Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat

Endocrinology

Volumn 144, Issue 3, 2003, Pages 785-792

  Sibonga, Jean D ^a   Lotinun, S ^a   Evans, G L ^a   Pribluda, V S ^c   Green, S J ^c   Turner, R T ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c ENTREMED INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; CHOLESTEROL; FULVESTRANT;

ADULTHOOD; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BONE GROWTH; BONE MASS; CANCELLOUS BONE; CELL GROWTH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; EPITHELIUM CELL; FEMALE; METAPHYSIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; TARGET ORGAN; TIBIA; UTERUS WEIGHT; WEANING; WEIGHT GAIN; WEIGHT REDUCTION;

AGING; ANIMALS; BODY WEIGHT; BONE AND BONES; BONE DEVELOPMENT; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; OSTEOPOROSIS; OVARIECTOMY; RATS; RECEPTORS, ESTROGEN; UTERUS; WEANING;

EID: 0037370558     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220632     Document Type: Article

References (38)

1. Zhu BT, Conney AH 1998 Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1-27
2. Martucci C, Fishman J 1979 Impact of continuous administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology 105:1288-1292
3. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ 1997 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 51:951-962
4. Cushman M, He HM, Katzenellenbogen JA, Varma RK, Lin CM, Hamel E, Ram S, Sachdeva YP 1997 Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J Med Chem 40:2323-2334
5. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L 1994 The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368:237-239
6. Pribluda VS, Gubish ER, LaVallee TM, Treston A, Swartz GM, Green SJ 2000 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev19:173-179
7. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T 1999 Potent antitumor activity, of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5:493-499
8. 2) suppresses proliferation and accelerates apoptosis in normal rat growth plate chondrocytes. J Cancer Res Clin Oncol 128:477-483
9. Wang SH, Myc A, Koenig RJ, Bretz JD, Arscott PL, Baker Jr JR 2000 2-Methoxestradiol, an endogenous estrogen metabolite, induces thyroid cell apoptosis. Mol Cell Endocrinol 165:163-172
10. Pico C, Puigserver P, Oliver P, Palou A 1998 2-Methoxyestradiol, an endogenous metabolite of 17β-estradiol, inhibits adipocyte proliferation. Mol Cell Biochem 189:1-7
11. Mukhopadhyay T, Roth JA 1997 Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14:379-384
12. LaVallee TM, Xhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS 2003 2-Methoxyestradiol upregulates DR5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63:468-475
13. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E 1994 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 92:3964-3968
14. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W 2000 Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390-395
15. Maran A, Zhang M, Kennedy AM, Sibonga JD, Rickard DJ, Spelsberg TC, Turner RT 2002 2-Methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells. Bone 30:393-398
16. Turner RT, Evans GL 2000 2-Methoxyestradiol inhibits longitudinal bone growth in normal female rats. Calcif Tissue Int 66:465-469
17. Turner RT, Evans GL, Sluka JP, Adrian MD, Bryant HU, Turner CH, Sato M 1998 Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene. Endocrinology 139:3712-3720
18. Parfitt A, Drezner M, Glorieux F, Kanis J, Malluche H, Meunier P, Ott S, Recker R 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
19. Wronski TJ, Lowry PL, Walsh CC, Ignaszewski LA 1985 Skeletal alterations in ovariectomized rats. Calcif Tissue Int 37:324-328
20. Turner RT, Evans GL, Wakley GK 1993 Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: inhibition of indices of formation and resorption. J Bone Miner Res 8:359-366
21. Turner RT, Vandersteenhoven JJ, Bell NH 1987 The effects of ovariectomy and 17β-estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res 2:115-122
22. Liu D, Bachmann KA 1998 An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats. J Pharmacol Exp Ther 286:561-568
23. Pribluda VS, LaVallee TM, Green SJ 2001 2-Methoxyestradiol: a novel endogenous chemotherapeutic and antiangiogenic agent. In: Fan TP, Kohn EC, eds. The new angiotherapy. Totowa, NJ: Humana Press
24. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS 2002 2-Methoxestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors α and β. Cancer Res 62:3691-3697
25. Wakeling AE 1995 Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol 49:1545-1549
26. Westerlind KC, Gibson KJ, Malone P, Evans GL, Turner RT 1998 Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. J Bone Miner Res 13:1023-1031
27. Lotinun S, Westerlind KC, Turner RT 2001 Tissue-selective effects of continuous release of 2-hydroxyestrone and 16α-hydroxyestrone on bone, uterus and mammary gland in ovariectomized growing rats. J Endocrinol 170:165-174
28. Maran A, Turner RT, Zhang M 2000 17β-Estradiol and a major metabolite 2-methoxyestradiol have different effects on gene expression in rat bone. J Bone Miner Res 15(Suppl 1):S325 (Abstract)
29. Evans G, Bryant HU, Magee D, Sato M, Turner RT 1994 The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134:2283-2288
30. Kalu DN, Liu CC, Salerno E, Hollis B, Echon R, Ray M 1991 Skeletal response of ovariectomized rats to low and high doses of 17β-estradiol. Bone Miner 14:175-187
31. Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD 1999 Is resveratrol an estrogen agonist in growing rats? Endocrinology 140:50-54
32. Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Warram J 1985 The metabolism of estradiol: oral compared to intravenous administration. J Steroid Biochem 23:1065-1070
33. Das SK, Taylor JA, Korach KS, Paria BC, Dey SK, Lubahn DB 1997 Estrogenic responses in estrogen receptor-α deficient mice reveal a distinct estrogen signaling pathway. Proc Natl Acad Sci USA 94:12786-12791
34. Miller KD, Haney LG, Pribluda VS, Sledge GW, A phase I safety pharmacokinetic and pharmacodynamic study of 2-methoxyestradiol (2ME2) in patients (Pts) with refractory metastatic breast cancer (MBC). Proc 37th Annual Meeting of the American Society of Clinical Oncologists, 2001, p 43 (Abstract 170)
35. Fendl KC, Ziminiski SJ 1992 Role of tamoxifen in the induction of hormone independent rat mammary tumors. Cancer Res 52:236-237
36. Sledge GW, Miller KD, Haney LG, Nguyen DD, Storniolo AM, Phillips EN, Pribluda VS, Gubish ER, A phase 1 study of 2-methoxyestradiol (2ME2) in patients (pts) with refractory metastatic breast cancer (MBC). Proc 38th Annual Meeting of the American Society of Clinical Oncology, 2002, Orlando, FL (Abstract 441)
37. Miller KD, Murry DJ, Curry E, Haney LG, McClaskey N, Storniolo AM, Phillips E, Pribluda VS, Gubish ER, Sledge GW, A phase 1 study of 2-methoxyestradiol (2ME2) plus docetaxel (D) in patients (pts) with metastatic breast cancer (MBC). Proc 38th Annual Meeting of the American Society of Clinical Oncology, 2002, Orlando, FL (Abstract 442)
38. Wilding G, Sweeney C, King DM, Horvath D, Staab MJ, Fife K, Armstrong V, Soriano JV, Pribluda VS, Gubish ER, Sidor C, Phase 2, multicenter randomized, double-blind, safety, pharmacokinetic, pharmacodynamic, and efficacy study of two doses of 2-methoxyestradiol administered orally in patients with hormone refractory prostate cancer. Proc 38th Annual Meeting of the American Society of Clinical Oncology, 2002, Orlando, FL (Abstract 338)